Base de dados : MEDLINE
Pesquisa : C18.452.394.984 [Categoria DeCS]
Referências encontradas : 22677 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2268 ir para página                         

  1 / 22677 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29416045
[Au] Autor:Basco D; Zhang Q; Salehi A; Tarasov A; Dolci W; Herrera P; Spiliotis I; Berney X; Tarussio D; Rorsman P; Thorens B
[Ad] Endereço:Center for Integrative Genomics, University of Lausanne, 1015, Lausanne, Switzerland.
[Ti] Título:α-cell glucokinase suppresses glucose-regulated glucagon secretion.
[So] Source:Nat Commun;9(1):546, 2018 02 07.
[Is] ISSN:2041-1723
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Glucagon secretion by pancreatic α-cells is triggered by hypoglycemia and suppressed by high glucose levels; impaired suppression of glucagon secretion is a hallmark of both type 1 and type 2 diabetes. Here, we show that α-cell glucokinase (Gck) plays a role in the control of glucagon secretion. Using mice with α-cell-specific inactivation of Gck (αGckKO mice), we find that glucokinase is required for the glucose-dependent increase in intracellular ATP/ADP ratio and the closure of K channels in α-cells and the suppression of glucagon secretion at euglycemic and hyperglycemic levels. αGckKO mice display hyperglucagonemia in the fed state, which is associated with increased hepatic gluconeogenic gene expression and hepatic glucose output capacity. In adult mice, fed hyperglucagonemia is further increased and glucose intolerance develops. Thus, glucokinase governs an α-cell metabolic pathway that suppresses secretion at or above normoglycemic levels; abnormal suppression of glucagon secretion deregulates hepatic glucose metabolism and, over time, induces a pre-diabetic phenotype.
[Mh] Termos MeSH primário: Células Secretoras de Glucagon/metabolismo
Glucagon/secreção
Glucoquinase/genética
Intolerância à Glucose/metabolismo
Glucose/metabolismo
Hipoglicemia/metabolismo
[Mh] Termos MeSH secundário: Difosfato de Adenosina/metabolismo
Trifosfato de Adenosina/metabolismo
Animais
Transporte Biológico
Feminino
Expressão Gênica
Células Secretoras de Glucagon/patologia
Glucoquinase/deficiência
Intolerância à Glucose/genética
Intolerância à Glucose/patologia
Hipoglicemia/genética
Hipoglicemia/patologia
Insulina/metabolismo
Canais KATP/genética
Canais KATP/metabolismo
Fígado/metabolismo
Masculino
Camundongos
Camundongos Knockout
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Insulin); 0 (KATP Channels); 61D2G4IYVH (Adenosine Diphosphate); 8L70Q75FXE (Adenosine Triphosphate); 9007-92-5 (Glucagon); EC 2.7.1.2 (Glucokinase); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180307
[Lr] Data última revisão:
180307
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE
[do] DOI:10.1038/s41467-018-03034-0


  2 / 22677 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29229629
[Au] Autor:Iacobucci G
[Ad] Endereço:The BMJ.
[Ti] Título:Student who died from anorexia was failed by NHS, review finds.
[So] Source:BMJ;359:j5731, 2017 12 11.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Anorexia/complicações
Falha da Terapia de Resgate/legislação & jurisprudência
Transtornos da Alimentação e da Ingestão de Alimentos/complicações
Medicina Estatal/ética
[Mh] Termos MeSH secundário: Causas de Morte/tendências
Inglaterra/epidemiologia
Falha da Terapia de Resgate/ética
Evolução Fatal
Transtornos da Alimentação e da Ingestão de Alimentos/diagnóstico
Feminino
Seres Humanos
Hipoglicemia/complicações
Pacientes Internados
Defesa do Paciente
Medicina Estatal/normas
Estudantes
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; NEWS
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.j5731


  3 / 22677 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Texto completo
[PMID]:29370218
[Au] Autor:Yale JF; Pettus JH; Brito-Sanfiel M; Lavalle-Gonzalez F; Merino-Trigo A; Stella P; Chevalier S; Buzzetti R
[Ad] Endereço:Department of Medicine, McGill University, Montreal, Canada.
[Ti] Título:The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3.
[So] Source:PLoS One;13(1):e0190579, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:AIMS: To evaluate the effect of concomitant dipeptidyl peptidase IV inhibitor (DPPIVi) use on efficacy and safety of insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in people with type 2 diabetes on oral antihyperglycaemic drugs. METHODS: A post hoc patient-level meta-analysis was performed using data from EDITION 2 (basal insulin [N = 811]) and EDITION 3 (insulin-naïve [N = 878]), multicentre, randomised, open-label, parallel-group, phase 3a trials of similar design. Endpoints analysed included HbA1c, hypoglycaemia and adverse events, investigated in subgroups of participants with and without concomitant DPPIVi use. RESULTS: Of 1689 participants randomised, 107 (13%, Gla-300) and 133 (16%, Gla-100) received DPPIVi therapy. The least squares mean change in HbA1c (baseline to month 6) was comparable between treatment groups, irrespective of DPPIVi use (no evidence of heterogeneity of treatment effect across subgroups, p = 0.753), although group sizes were unbalanced. The cumulative mean number of confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemic events, and the risk and annualised rate of such events, were consistently lower for Gla-300 than Gla-100 during the night (between 00:00 and 05:59 h) or at any time of day (24 h period), irrespective of DPPIVi use. Severe hypoglycaemia occurred in 8/838 and 10/844 participants in the Gla-300 and Gla-100 groups, respectively, and was not affected by DPPIVi use. The adverse event profile was similar between treatment groups and DPPIVi subgroups. CONCLUSIONS: Glycaemic control with Gla-300 was comparable to Gla-100, with less hypoglycaemia during the night and at any time of day (24 h), irrespective of concomitant DPPIVi use. TRIAL REGISTRATION: ClinicalTrials.gov NCT01499095; NCT01676220.
[Mh] Termos MeSH primário: Glicemia/análise
Diabetes Mellitus Tipo 2/tratamento farmacológico
Inibidores da Dipeptidil Peptidase IV/uso terapêutico
Hipoglicemia/tratamento farmacológico
Hipoglicemiantes/uso terapêutico
Insulina Glargina/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Peso Corporal
Diabetes Mellitus Tipo 2/sangue
Relação Dose-Resposta a Droga
Quimioterapia Combinada
Feminino
Seres Humanos
Insulina Glargina/administração & dosagem
Masculino
Meia-Idade
Estudos Multicêntricos como Assunto
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Dipeptidyl-Peptidase IV Inhibitors); 0 (Hypoglycemic Agents); 2ZM8CX04RZ (Insulin Glargine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190579


  4 / 22677 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29260924
[Au] Autor:Molina Vega M; Muñoz-Garach A; Tinahones FJ
[Ad] Endereço:a Department of Endocrinology and Nutrition , Virgen de la Victoria Hospital, Málaga University (IBIMA). , Málaga , Spain.
[Ti] Título:Pharmacokinetic drug evaluation of exenatide for the treatment of type 2 diabetes.
[So] Source:Expert Opin Drug Metab Toxicol;14(2):207-217, 2018 02.
[Is] ISSN:1744-7607
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Glucagon-like peptide-1 (GLP-1) receptor analogs are a group of therapeutic agents which mimic endogenous GLP-1, exerting their effect by the stimulation of the GLP-1 receptor with a wide distribution. Its activation increases insulin releasing dependent on blood glucose levels, suppression of glucagon secretion and a reduction of hepatic glucose output. It delays gastric emptying and increases satiety. Exenatide is the synthetic version of exendin-4, a natural peptide with similar properties to human GLP-1. There are two pharmaceutical forms, for subcutaneous injection: twice daily and once weekly. Clinical practice guidelines recommend them because of a high efficacy reducing hyperglycemia, low risk of hypoglycemia and a significative weight loss effect. Gastrointestinal adverse events are the most common beside injection site-related. Their cost is the main limitation to use. Areas covered: We review the recent literature investigating the pharmacokinetics and pharmacodynamics and efficacy-safety studies of exenatide twice daily and once weekly in type 2 diabetes Expert opinion: GLP-1 receptor analogs are now positioned as an effective and safe drug for the treatment of type 2 diabetes. Exenatide significally reduces HbA1c and fasting plasma glucose. Additionally, it produces moderate weight loss and decreases blood pressure. One weekly formulation may improve compliance while cost is still a limitation. EXSCEL trial has shown that, despite cardiovascular safety, exenatide do not exhibits cardiovascular benefits.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2/tratamento farmacológico
Hipoglicemiantes/administração & dosagem
Peptídeos/administração & dosagem
Peçonhas/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Glicemia/efeitos dos fármacos
Esquema de Medicação
Receptor do Peptídeo Semelhante ao Glucagon 1/agonistas
Seres Humanos
Hipoglicemia/induzido quimicamente
Hipoglicemiantes/farmacocinética
Hipoglicemiantes/farmacologia
Injeções Subcutâneas
Insulina/metabolismo
Peptídeos/farmacocinética
Peptídeos/farmacologia
Peçonhas/farmacocinética
Peçonhas/farmacologia
Perda de Peso/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Glucagon-Like Peptide-1 Receptor); 0 (Hypoglycemic Agents); 0 (Insulin); 0 (Peptides); 0 (Venoms); 9P1872D4OL (exenatide)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE
[do] DOI:10.1080/17425255.2018.1420160


  5 / 22677 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464825
[Au] Autor:Madrid L; Sitoe A; Varo R; Nhampossa T; Lanaspa M; Nhama A; Acácio S; Riaño I; Casellas A; Bassat Q
[Ad] Endereço:Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique.
[Ti] Título:Continuous determination of blood glucose in children admitted with malaria in a rural hospital in Mozambique.
[So] Source:Malar J;16(1):184, 2017 05 02.
[Is] ISSN:1475-2875
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hypoglycaemia is a frequent complication among admitted children, particularly in malaria-endemic areas. This study aimed to estimate the occurrence of hypoglycaemia not only upon admission but throughout the first 72 h of hospitalization in children admitted with malaria. METHODS: A simple pilot study to continuously monitor glycaemia in children aged 0-10 years, admitted with malaria in a rural hospital was conducted in Southern Mozambique by inserting continuous glucose monitors (CGMs) in subcutaneous tissue of the abdominal area, producing glycaemia readings every 5 min. RESULTS: Glucose was continuously monitored during a mean of 48 h, in 74 children. Continuous measurements of blood glucose were available for 72/74 children (97.3%). Sixty-five of them were admitted with density-specific malaria diagnosis criteria (17 severe, 48 uncomplicated). Five children (7.7%) had hypoglycaemia (<54 mg/dL) on admission as detected by routine capillary determination. Analysing the data collected by the CGMs, hypoglycaemia episodes (<54 mg/dL) were detected in 10/65 (15.4%) of the children, of which 7 (10.8%) could be classified as severe (≤45 mg/dL). No risk factors were independently associated with the presence of at least one episode of hypoglycaemia (<54 mg/dL) during hospitalization. Only one death occurred among a normoglycaemic child. All episodes of hypoglycaemia detected by CGMs were subclinical episodes or not perceived by caregivers or clinical staff. CONCLUSIONS: Hypoglycaemia beyond admission in children with malaria appears to be much more frequent than what had been previously described. The clinical relevance of these episodes of hypoglycaemia in the medium or long term remains to be determined.
[Mh] Termos MeSH primário: Glicemia/análise
Hospitais Rurais/estatística & dados numéricos
Hipoglicemia/epidemiologia
[Mh] Termos MeSH secundário: Criança
Pré-Escolar
Feminino
Seres Humanos
Hipoglicemia/etiologia
Lactente
Malária/complicações
Masculino
Moçambique/epidemiologia
Projetos Piloto
Prevalência
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Blood Glucose)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s12936-017-1840-x


  6 / 22677 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29223210
[Au] Autor:Neczypor JL; Holley SL
[Ti] Título:Providing Evidence-Based Care During the Golden Hour.
[So] Source:Nurs Womens Health;21(6):462-472, 2017 Dec.
[Is] ISSN:1751-486X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The Golden Hour encompasses a set of evidence-based practices that contribute to the physiologic stabilization of the mother-newborn dyad after birth. Important elements of the Golden Hour include delayed cord clamping, skin-to-skin contact for at least an hour, the performance of newborn assessments on the maternal abdomen, delaying non-urgent tasks (e.g., bathing the newborn) for 60 minutes, and the early initiation of breastfeeding. The Golden Hour contributes to neonatal thermoregulation, decreased stress levels in a woman and her newborn, and improved mother-newborn bonding. Implementation of these actions is further associated with increased rates and duration of breastfeeding. This article explores the evidence supporting the Golden Hour and provides strategies for successfully implementing a Golden Hour protocol on a hospital-based labor and delivery unit.
[Mh] Termos MeSH primário: Prática Clínica Baseada em Evidências/métodos
Parto
Fatores de Tempo
[Mh] Termos MeSH secundário: Aleitamento Materno/métodos
Feminino
Guias como Assunto/normas
Seres Humanos
Hipoglicemia/prevenção & controle
Hipotermia/prevenção & controle
Recém-Nascido
Gravidez
Cordão Umbilical/cirurgia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:171211
[St] Status:MEDLINE


  7 / 22677 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27776567
[Au] Autor:Roopan S; Larsen ER
[Ad] Endereço:1Psychiatric Department Kolding-Vejle,Region of Southern Denmark,Denmark.
[Ti] Título:Use of antidepressants in patients with depression and comorbid diabetes mellitus: a systematic review.
[So] Source:Acta Neuropsychiatr;29(3):127-139, 2017 Jun.
[Is] ISSN:1601-5215
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Depression may be difficult to treat and with comorbid diabetes mellitus (DM) it is an even bigger challenge. This article aims to evaluate antidepressants most suitable for patients with depression and comorbid DM. Design and methods Initially we searched for randomised, controlled double-blind trials of treatment with antidepressants in depressed with DM but there were only a few studies and many of them were small trials. Thus, we decided to include studies that were not only randomised-controlled trials. In total, we ended up with 18 articles for our purposes. RESULTS: The combination of depression and DM may be harmful as depression has a strong impact on psychosocial and medical outcomes in patients with DM. Almost all of the trials in this review showed a reduction in depressive symptoms after treatment with an antidepressant in the acute as well as during maintenance phase. It showed that depression improvement had a favourable effect on glycaemic control that was weight independent. Some studies included only subjects with minor depression or with suboptimal-controlled diabetes making it difficult to show an effect. CONCLUSION: From these data, we will recommend choosing an selective serotonin reuptake inhibitor (SSRI) if possible to treat a depression among patients with diabetes. If treatment with a tricyclic antidepressant is needed, closer glycaemic monitoring is recommended. Bear in mind that there is a possible risk of hypoglycemia when using SSRIs. Agomelatine and bupropion have shown promising results, but need to be investigated in more trials.
[Mh] Termos MeSH primário: Antidepressivos/uso terapêutico
Comorbidade
Depressão/tratamento farmacológico
Diabetes Mellitus/psicologia
[Mh] Termos MeSH secundário: Acetamidas/efeitos adversos
Acetamidas/uso terapêutico
Adulto
Idoso
Antidepressivos/efeitos adversos
Antidepressivos de Segunda Geração/administração & dosagem
Antidepressivos de Segunda Geração/uso terapêutico
Antidepressivos Tricíclicos/efeitos adversos
Antidepressivos Tricíclicos/uso terapêutico
Bupropiona/efeitos adversos
Bupropiona/uso terapêutico
Depressão/complicações
Diabetes Mellitus/tratamento farmacológico
Método Duplo-Cego
Feminino
Seres Humanos
Hiperglicemia/induzido quimicamente
Hiperglicemia/complicações
Hipnóticos e Sedativos/efeitos adversos
Hipnóticos e Sedativos/uso terapêutico
Hipoglicemia/induzido quimicamente
Hipoglicemia/complicações
Masculino
Meia-Idade
Ensaios Clínicos Controlados Aleatórios como Assunto
Inibidores da Captação de Serotonina/efeitos adversos
Inibidores da Captação de Serotonina/uso terapêutico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Acetamides); 0 (Antidepressive Agents); 0 (Antidepressive Agents, Second-Generation); 0 (Antidepressive Agents, Tricyclic); 0 (Hypnotics and Sedatives); 0 (Serotonin Uptake Inhibitors); 01ZG3TPX31 (Bupropion); 138112-76-2 (S 20098)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1017/neu.2016.54


  8 / 22677 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29334278
[Au] Autor:Consoli A; Formoso G; Baldassarre MPA; Febo F
[Ad] Endereço:a Department of Medicine and Aging Sciences; Aging and Translational Medicine Research Center (CeSI-Met) , G. d'Annunzio University , Chieti , Italy.
[Ti] Título:A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment.
[So] Source:Expert Opin Drug Saf;17(3):293-302, 2018 Mar.
[Is] ISSN:1744-764X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose cotransporter 2 inhibitors (SGLT2i) are of particular interest in type 2 diabetes treatment strategies, due to their efficacy in reducing HbA1c with a low risk of hypoglycaemia, to their positive effects on body weight and blood pressure and in light of their effects on cardiovascular risk and on nephroprotection emerged from the most recent cardiovascular outcome trials. Since it is therefore very likely that GLP-1RA and SGLT2i use will become more and more common, it is more and more important to gather and discuss information about their safety profile. Area Covered: adverse events and the safety concerns most often emerged in trials with GLP-1RA namely, exenatide long acting release (LAR), dulaglutide, liraglutide, semaglutide, lixisenatide or SGLT2i, namely empagliflozin, dapagliflozin, canagliflozin and SGLT2i with an attempt at comparing the safety profiles of molecules of these two classes. Expert opinion: GLP-1RA and SGLT2i, although each associated with different specific side effects, share a 'similar' safety profile and are both drugs relatively easy to handle. The potentially complementary mechanisms of action, the cardio and nephroprotective effects demonstrated by molecules of both classes, make these drugs potentially useful even in add on to each other.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2/tratamento farmacológico
Receptor do Peptídeo Semelhante ao Glucagon 1/agonistas
Hipoglicemiantes/efeitos adversos
Transportador 2 de Glucose-Sódio/antagonistas & inibidores
[Mh] Termos MeSH secundário: Hemoglobina A Glicada/metabolismo
Seres Humanos
Hipoglicemia/induzido quimicamente
Hipoglicemiantes/farmacologia
Hipoglicemiantes/uso terapêutico
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Glucagon-Like Peptide-1 Receptor); 0 (Glycated Hemoglobin A); 0 (Hypoglycemic Agents); 0 (SLC5A2 protein, human); 0 (Sodium-Glucose Transporter 2)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180116
[St] Status:MEDLINE
[do] DOI:10.1080/14740338.2018.1428305


  9 / 22677 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390469
[Au] Autor:Zeng XX; Tang YL; Hu KX; Wang J; Zhu LY; Liu JY; Xu J
[Ad] Endereço:Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
[Ti] Título:Insulin autoimmune syndrome in a pregnant female: A rare case report.
[So] Source:Medicine (Baltimore);96(51):e9213, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Insulin autoimmune syndrome (IAS) is an uncommon disorder characterized by hyperinsulinemic hypoglycemia related to insulin-binding autoantibodies. To the best of our knowledge, we report the first case of a pregnant female with IAS. PATIENT CONCERNS: The 26-year-old patient with Graves disease and 10 weeks pregnant developed IAS after approximately 6 months treatment with methimazole. The patient exhibited recurrent spontaneous hypoglycemia. DIAGNOSES: On evaluation, laboratory findings detected both high fasting insulin (>1000 mIU/L) and insulin autoantibodies. An oral glucose tolerance test showed elevated insulin concentrations with disproportionately elevated C-peptide levels. The imaging study showed nomasslesionsinthepancreas,and the patient was clinically diagnosed with IAS. INTERVENTIONS: The patient had an abortion, discontinued methimazole and switched to oral prednisone (30 mg once daily) and propylth- iouracil (100 mg 3 times daily) for 3 months. OUTCOMES: At the 3-month follow-up visit, hypoglycemic episodes had disappeared and insulin antibody levels were no longer detectable. LESSONS: We have described this case and reviewed the relevant literature concerning diagnosis and treatment of IAS. Importantly, this case indicates that clinicians should view pregnancy as another factor of hypoglycemia in IAS.
[Mh] Termos MeSH primário: Doenças Autoimunes/diagnóstico
Hipoglicemia/induzido quimicamente
Insulina/sangue
Metimazol/efeitos adversos
Complicações na Gravidez/diagnóstico
[Mh] Termos MeSH secundário: Aborto Espontâneo
Adulto
Feminino
Seguimentos
Idade Gestacional
Doença de Graves/diagnóstico
Doença de Graves/tratamento farmacológico
Seres Humanos
Hipoglicemia/imunologia
Hipoglicemia/fisiopatologia
Insulina/imunologia
Anticorpos Anti-Insulina/sangue
Metimazol/uso terapêutico
Prednisona/uso terapêutico
Gravidez
Doenças Raras
Medição de Risco
Síndrome
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Insulin); 0 (Insulin Antibodies); 554Z48XN5E (Methimazole); VB0R961HZT (Prednisone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009213


  10 / 22677 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29320619
[Au] Autor:Dragovic T; Marinkovic D; Kikovic S; Pejovic J; Hajdukovic Z
[Ti] Título:Some specificities in the management of hyperglycemia in patients with diabetic kidney disease.
[So] Source:Vojnosanit Pregl;73(9):857-63, 2016 Sep.
[Is] ISSN:0042-8450
[Cp] País de publicação:Serbia
[La] Idioma:eng
[Mh] Termos MeSH primário: Glicemia/efeitos dos fármacos
Diabetes Mellitus/tratamento farmacológico
Nefropatias Diabéticas/terapia
Hipoglicemiantes/administração & dosagem
Diálise Renal
Insuficiência Renal Crônica/terapia
[Mh] Termos MeSH secundário: Biomarcadores/sangue
Glicemia/metabolismo
Diabetes Mellitus/sangue
Diabetes Mellitus/epidemiologia
Nefropatias Diabéticas/sangue
Nefropatias Diabéticas/epidemiologia
Cálculos da Dosagem de Medicamento
Seres Humanos
Hipoglicemia/sangue
Hipoglicemia/induzido quimicamente
Hipoglicemia/prevenção & controle
Hipoglicemiantes/efeitos adversos
Rim/efeitos dos fármacos
Rim/fisiopatologia
Diálise Renal/efeitos adversos
Insuficiência Renal Crônica/sangue
Insuficiência Renal Crônica/epidemiologia
Insuficiência Renal Crônica/fisiopatologia
Fatores de Risco
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers); 0 (Blood Glucose); 0 (Hypoglycemic Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.2298/VSP150321008D



página 1 de 2268 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde